H-Share issue approved Shanghai medicine take 20 billion orders

April 12, Shanghai Pharmaceutical (601607, close 19.49 Yuan) issued a notice, the CSRC approved its issuance of not more than 765 million shares (including excess placement of 99,632,167 shares), is expected to raise funds of about 8 billion yuan. The approval of H-share issuance has added to the firm's clout. Yesterday (April 12), the company officially announced the joint 69 multinational pharmaceutical companies to deepen large-scale cooperation in batches. The specific scope of cooperation and objectives involved "in 2011, with Pfizer, Sanofi-Aventis, Merck, Connaught and Connaught, Abbott and other multinational drug companies signed the total amount of the agreement will exceed 20 billion yuan, accounting for the current new national distribution business 60%." Li Yongzhong, vice president of Shanghai Pharmaceutical Marketing, said: "In addition to further cooperation with multinational pharmaceutical companies in distribution, retail, the new medicine also hopes to work with the transnational pharmaceutical companies in drug development and registration, government affairs, commissioned processing, joint development and promotion of potential products, such as in-depth cooperation."　　"Taking the Citic Medicine as the Platform Foundation, the squad of the market after seeking the trans-regional development is also gradually clear." "Good" drug giants learned that the above 20 billion yuan procurement, mainly related to the multinational drug companies under the high-end drugs, high-value supplies and vaccine products. "The current share of these multinational companies in China is about 10%~12%, and we hope to reach around 30% in the future."　　"The medicine is disclosed.　　In the 69 pharmaceutical companies, according to Pfizer China general manager Wuxiao revealed that at present only a Pfizer foreign companies, and the medicine cooperation business has 3 billion yuan.　　Pack and sign this "big list" after long-term with the Chinese medicine Group, China Resources Group Close melee of the drug seems to hope to complete the acquisition of the Citic Medical platform, combined with a number of multinational pharmaceutical companies continue to expand the market share of high-end products, to seek new business growth. In fact, according to public information show: "Alongside on" a large number of foreign drug companies to purchase the new medicine itself in the equipment, High-value supplies business market is currently ranked top in the industry, and in the vaccine business is located in the second.　　More than 20 billion of the purchase orders with the pharmaceutical giant will continue to tamp down the company's dominance in these markets. Medicine on the cooperation with the 69 companies also placed high hopes: "In Beijing, Shanghai, Guangzhou, three of China's drug consumption market for 20% of the mega-city, for suppliers to provide new products on the list of the fastest coverage of other competitors faster, to the shortest possible time to complete the product coverage of the hospital." "The acquisition of Citic Pharmaceutical high-end market, April 7, the Shanghai Medical Bulletin said the NDRC agreed to buy China Health Systems Co., Ltd. (CHINAHEALTHSYSTEMLTD, hereinafter referred to as CHS) 100% equity.　　Public information also shows that CHS's substantive assets are CITIC Medicine 100% Equity, that is, Citic Medicine officially become a subsidiary. "After the board resolution and the National Development and Reform Commission administrative approval, the acquisition of CHS required most of the processOrder is complete. "The official said in an interview with the Daily economic news," there is no obstacle to the transfer of shares after approval.　　"As the largest mergers and acquisitions since the new medicine, pharmaceutical group has been the acquisition of Citic Pharmaceuticals has been regarded as the further development of Beijing, Tianjin and Hebei, and then layout of the country's important steps." "After the acquisition of Citic Medicine and the previous acquisition of Love Albert, in fact, as a medicine in North China, an important platform."　　And after the acquisition of integration is also around the business docking, drug development and integration of varieties and IT systems and other aspects of the active development, the Shanghai Medical Group Board office staff Land to the "daily economic news" said. Land further pointed out: "Before the acquisition, on the medicine and CITIC Management there are communication and transformation of the integration program."　　Now after the takeover, the group decided to retain all Citic management, after all, management is very important to the company. On the one hand, through internal integration, the formation of an integrated national distribution platform, on the other hand, shaping the high-end drugs, equipment, high-value supplies and vaccines in the field of differentiated strategic advantages.　　"In high-end supplies, vaccines, high-value drugs direct delivery services in these three areas to form a core advantage," said Lu Mingfang, chairman of the pharmaceutical group.　　Some insiders pointed out that the original in the high-end field has no obvious advantages of the medicine group, is to borrow the original flagship high-end products of the Citic Medical to share this piece of "cake on the cream."　　The expansion plan will also continue to buy Citic Pharmaceuticals as a national step in the company's layout and may have continued expansion plans in the future. "On the purchase of Pianan in North China, the next step may be to help its development to the surrounding areas of North China business, which does not exclude the way through mergers and acquisitions or other organic growth, whether it is the above pharmaceutical group or Citic Medicine as a subsidiary of the expansion, are very likely." However, these acquisitions were made after the completion of the pharmaceutical Citic Integration and the timing was appropriate.　　"The land pointed out. It is reported that the protagonist of the acquisition of Citic Pharmaceutical business mainly in the Beijing market, ranked third in the local market share, of which the hospital distribution business accounted for 70%, 2010 sales income of more than 6 billion yuan.　　Earlier this year, if the purchase of Citic Medicine and the market share of Love Albert, Shanghai Medicine in the Beijing pharmaceutical distribution market share for the first time than the Chinese Medicine Holdings, ranked second only to the local first North medicine stake. Guotai Pharmaceutical industry analyst Yi Jing Ming said, after the completion of the purchase of Citic Medicine, the initial realization of East China, South China, north China as the focus of the national pharmaceutical Distribution network.　　In the next few years the company's business development plan is to consolidate the market share of East China first, accelerate the development of South China (Zhongshan Medicine platform) and North China (Citic Medicine platform). "The company's future acquisition may be based on the quality of the premise, not purely for the size of mergers and acquisitions, currently not considered in the drug market capacity of small areas to establish a large distribution network."　　Isheming points out. According to the previous 2010 years of MedicineNewspaper data show: "The group has developed a nationwide distribution network through more than 40 subsidiaries and subsidiaries and more than 30 logistics centers through selective and steady expansion of its external mergers and acquisitions of industrial and commercial sectors, focusing on the direct distribution of products to hospitals and other medical institutions, including community medical centres and clinics. But medicine is not the only one with ambition layout nationwide drug companies, whether it is the domestic pharmaceutical circulation giant Chinese Medicine group, won the North China Resources soon, or the listing of Kyushu Pass, the competition has to the white-hot level. "Because the Chinese medicine and Kyushu have basically achieved the national layout, and the medicine is still mainly in east China market, so the future of medicine has a long way to go." "Guofan, a researcher in the pharmaceutical industry from CIC, said of the daily economic news." Responsible Editor: NF045